Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate

Sheba Medical Center

Status: Unknown

Conditions: Multiple Sclerosis

Treatments: Drug: Glatiramer acetate

Study type: Interventional

Funder types: Other

Identifiers

NCT00331747

SHEBA-05-3985-UG-CTIL

Details and patient eligibility

About

Hypothesis: Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis (MS) patients.

During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment.

Full description

Patients with a definite diagnosis of relapsing remitting multiple sclerosis (MS) will undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate. The gait analysis will include kinematic evaluation using a Charnwood Dynamics CODA CX-1 system, 4 AMTI force plates and a Noraxon telemetric EMG system. Patients will be videotaped and will also undergo a detailed physical examination by a physical therapist.

Treatment with Glatiramer acetate will be initiated after the gait analysis. Therapy will be observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center.

Repeat gait analysis will be performed after one year of treatment.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of multiple sclerosis
• EDSS less than 5.5
• No cognitive disability

Exclusion criteria

• EDSS over 5.5
• Inability to cooperate with gait analysis

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)